Press Releases
- Active Biotech announces start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops
- Active Biotech Year End Report 2023
- Number of shares and votes in Active Biotech
- Active Biotech provides update on the scheduled clinical program for 2024
- Positive preclinical tasquinimod data presented at ASH 2023 now available on Active Biotech’s website